MMRGlobal Reports Record Revenue for 2014 - Seite 2

Furthermore, in these days of Cyber theft and hacking, the Company has designed its platform in a manner that protects the integrity of personally controlled health information by storing the data in encrypted image files even when at rest. This means that each medical record (document) is encrypted at all times when residing in MMR's storage systems and can only be accessed in a viewable form when the authorized user, family member or healthcare professional has proper authentication AND credentials to view that medical record (document). This is especially important at this time when theft of medical records is prevalent and widely reported in the media because, even if an unforeseen massive data breach occurred at a hosting facility, any encrypted documents would not be viewable by an unauthorized entity.

While the build-up of health IT (HIT) solutions expands in the United States, the Company also participates in health IT globally. Wall Street continues to remain bullish on health information technology, and biotech, both of which are the subject of the Company's portfolio of U.S. and foreign patents. Through its wholly owned subsidiary, MyMedicalRecords, Inc., the Company currently has health IT patents issued, pending and/or applied for in the United States and 11 other countries or regional authorities of commercial interest including Australia, Singapore, New Zealand, Mexico, Japan, Canada, Hong Kong, China, South Korea, Israel and Europe. In the U.S., MMR currently has 13 issued health IT patents including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; 8,321,240; 8,498,883; 8,626,532, 8,645,161; 8,725,537; 8,768,725 and 8,775,212, as well as additional applications and continuation applications pertaining to Personal Health Records, Patient Portals and Electronic Health Records. MMR is also beginning to capture opportunities in the Middle East starting in Kuwait, where a higher percentage of the population is comprised of Expats and health information technology is also driven by medical tourism. Additionally, MMR has a large and growing portfolio of biotech patents which it acquired through the Company's 2009 reverse merger with Favrille, Inc. These assets have particular utility for the treatment of B-cell mediated cancers such as Non-Hodgkin's lymphoma and other diseases of the immune system, and include patient samples owned and/or controlled by the Company. To date, MMR has six biotechnology patents issued by the United States Patent and Trademark Office, additional patents issued in Australia, South Korea, Mexico, Singapore, Hong Kong, Japan and throughout Europe, and patents pending in various other countries of commercial interest.